Acadia declares early win on Nuplazid dementia study, stunning analysts and sending shares soaring
Acadia Pharmaceuticals — maker of the controversial psychosis drug Nuplazid — is halting a late-stage trial in patients with dementia after the company reported it had obtained enough positive data at an interim readout to make its pitch to the FDA.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
